Tildrakizumab
- Generic Name
- Tildrakizumab
- Brand Names
- Ilumya, Ilumetri
- Drug Type
- Biotech
- CAS Number
- 1326244-10-3
- Unique Ingredient Identifier
- DEW6X41BEK
- Background
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .
The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter .
A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects .
- Indication
Moderate-severe plaque psoriasis , .
- Associated Conditions
- Moderate to Severe Plaque Psoriasis
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Psoriasis Treatment Center of Central New Jersey
- Target Recruit Count
- 25
- Registration Number
- NCT04347473
- Locations
- 🇺🇸
Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- Conditions
- PsoriasisPsoriasis Vulgaris
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 244
- Registration Number
- NCT04340076
- Locations
- 🇳🇱
Amphia Hospital, Breda, Netherlands
🇳🇱Radboudumc, Nijmegen, Netherlands
🇳🇱Máxima Medisch Centrum, Veldhoven, Netherlands
MIcrovascular dysfuNction In Moderate-severe Psoriasis
- Conditions
- PsoriasisCardiovascular Disease
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Marcelo F. Di Carli, MD, FACC
- Target Recruit Count
- 36
- Registration Number
- NCT04271540
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: Dimethyl fumarate (DMF) standard schemeDrug: Dimethyl fumarate (DMF) simplified scheme
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 190
- Registration Number
- NCT04263610
- Locations
- 🇩🇪
Investigator Site 3, Augsburg, Germany
🇬🇧Investigator Site 2, London, United Kingdom
🇬🇧Investigator Site 1, Bristol, United Kingdom
Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 178
- Registration Number
- NCT04229836
- Locations
- 🇪🇸
Investigator Site 8, Madrid, Spain
🇪🇸Investigator Site 9, Madrid, Spain
🇮🇹Investigator Site 10, Novara, Italy
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 331
- Registration Number
- NCT04203693
- Locations
- 🇳🇱
Investigational site 1, Breda, Netherlands
🇮🇹Investigational site 5, Roma, Italy
🇩🇪Investigational site 13, Berlin, Germany
Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 51
- Registration Number
- NCT04112810
- Locations
- 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
- Conditions
- Moderate-to-severe Chronic Plaque Psoriasis
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 130
- Registration Number
- NCT03997786
- Locations
- 🇵🇱
Site 57, Bialystok, Poland
🇵🇱Site 55, Gdańsk, Poland
🇵🇱Site 51, Katowice, Poland
Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab
- Conditions
- Pregnancy Related
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 200
- Registration Number
- NCT03992729
- Locations
- 🇺🇸
Christina Chambers, San Diego, California, United States
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
- Conditions
- Chronic Plaque PsoriasisModerate to Severe Nail Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 99
- Registration Number
- NCT03897075
- Locations
- 🇺🇸
California Dermatology & CRI (Site 18), Encinitas, California, United States
🇺🇸First OC Dermatology (Site 07), Fountain Valley, California, United States
🇺🇸Dermatology Research Associates (Site 09), Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.